#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	9898	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2087	467.6	0	.	n	.	0	C1450T	SNP	1450	1450	C	1714	1714	T	533	T,C	504,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	9898	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2087	467.6	1	SNP	n	C1184T	0	.	.	1184	1184	C	1448	1448	C	596	C	569	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	18740	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3577	517.8	0	.	n	.	0	G1337A	SNP	1337	1337	G	1604	1604	A	623	A	596	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	18740	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3577	517.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2238	2238	C	599	C	569	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	18740	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3577	517.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2312	2312	A	597	A	570	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	18740	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3577	517.8	1	SNP	n	C2597T	0	.	.	2597	2597	C	2864	2864	C	579	C,T	556,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	1286	folP	855	855	100.0	folP.l15.c4.ctg.1	1464	86.6	1	SNP	p	R229S	1	.	.	685	687	AGC	1021	1023	AGC	141;139;138	A;G;C	137;137;135	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	3370	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3464	96.1	1	SNP	p	S91F	1	.	.	271	273	TTC	632	634	TTC	92;90;91	T;T;C	88;86;86	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	3370	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3464	96.1	1	SNP	p	G95N	0	.	.	283	285	GGC	644	646	GGC	90;90;89	G;G;C	86;84;85	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	3370	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3464	96.1	1	SNP	p	D95G	1	.	.	283	285	GGC	644	646	GGC	90;90;89	G;G;C	86;84;85	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	27	1220	mtrR	633	633	100.0	mtrR.l15.c17.ctg.1	1364	88.7	1	SNP	p	G45D	0	.	.	133	135	GGC	493	495	GGC	150;147;146	G,T;G;C,G	143,1;143;141,1	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	536	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c17.ctg.1	1039	51.0	0	.	n	.	0	A197.	DEL	197	197	A	619	619	A	117	A	113	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3042	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3115	96.6	1	SNP	p	D86N	0	.	.	256	258	GAC	607	609	GAC	128;128;126	G;A;C	122;121;121	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3042	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3115	96.6	1	SNP	p	S87R	1	.	.	259	261	CGT	610	612	CGT	125;127;128	C;G;T	121;120;117	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3042	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3115	96.6	1	SNP	p	R87I	0	.	.	259	261	CGT	610	612	CGT	125;127;128	C;G;T	121;120;117	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3042	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3115	96.6	1	SNP	p	R87W	0	.	.	259	261	CGT	610	612	CGT	125;127;128	C;G;T	121;120;117	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3042	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3115	96.6	1	SNP	p	S88P	0	.	.	262	264	TCC	613	615	TCC	128;129;131	T;C;C	120;119;124	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	2712	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2747	97.7	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1296	1298	TGC	113;114;113	T;G;C,T	104;101;101,1	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	2712	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2747	97.7	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1506	1508	GGC	122;122;123	G;G;C	118;119;119	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	2664	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2388	109.7	1	SNP	p	A311V	0	.	.	931	933	GCA	1231	1233	GCA	142;142;145	G;C;A,C	135;138;142,1	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	2664	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2388	109.7	1	SNP	p	I312M	0	.	.	934	936	ATC	1234	1236	ATC	147;147;147	A;T;C,G	144;141;142,1	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	2664	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2388	109.7	1	SNP	p	V316P	0	.	.	946	948	GTG	1246	1248	GTG	150;149;149	G;T,C;G,C	137;136,1;137,1	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	2664	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2388	109.7	1	SNP	p	V316T	0	.	.	946	948	GTG	1246	1248	GTG	150;149;149	G;T,C;G,C	137;136,1;137,1	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	2664	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2388	109.7	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1750	1752	ACC	127;129;128	A;C;C	120;125;124	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	2664	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2388	109.7	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1804	1806	GCG	129;128;129	G;C,A;G	125;113,1;123	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	2664	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2388	109.7	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1804	1806	GCG	129;128;129	G;C,A;G	125;113,1;123	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	2664	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2388	109.7	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1927	1929	GGC	98;97;96	G;G;C	94;93;94	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	2664	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2388	109.7	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1936	1938	GGC	92;92;93	G;G;C	86;87;88	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	2664	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2388	109.7	1	SNP	p	P552S	1	.	.	1654	1656	TCG	1954	1956	TCG	95;95;92	T,G;C,G;GCCC,GCCCC	65,11;77,2;68,1	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	4004	ponA	2397	2397	100.0	ponA.l6.c4.ctg.1	3237	121.9	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1724	1726	CCG	121;122;123	C;C;G	112;121;120	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	1488	porA	1146	1146	99.56	porA.l15.c4.ctg.1	1705	85.9	0	.	p	.	0	M83fs	FSHIFT	247	247	A	552	552	C	98	C,G	92,1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	240	porB1a	984	271	91.14	porB1a.l6.c30.ctg.2	436	18.3	0	.	p	.	0	V258L	NONSYN	772	774	GTA	99	101	TTA	33;34;33	T;T;A	30;31;30	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	240	porB1a	984	271	91.14	porB1a.l6.c30.ctg.2	436	18.3	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	144	146	CAT	34;32;29	C;A;T	32;30;28	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	240	porB1a	984	271	91.14	porB1a.l6.c30.ctg.2	436	18.3	0	.	p	.	0	D274S	NONSYN	820	822	GAT	147	149	AGT	29;29;29	A;G;T	28;27;28	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	240	porB1a	984	271	91.14	porB1a.l6.c30.ctg.2	436	18.3	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	156	158	TAC	29;31;31	T;A;C	28;29;29	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	240	porB1a	984	271	91.14	porB1a.l6.c30.ctg.2	436	18.3	0	.	p	.	0	R307A	NONSYN	919	921	AGA	246	248	GCA	13;13;13	G;C;A	13;13;13	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	240	porB1a	984	271	91.14	porB1a.l6.c30.ctg.2	436	18.3	0	.	p	.	0	T311A	NONSYN	931	933	ACA	258	260	GCA	10;10;10	G;C;A	10;10;10	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	240	porB1a	984	271	91.14	porB1a.l6.c30.ctg.2	436	18.3	0	.	p	.	0	E312V	NONSYN	934	936	GAA	261	263	GTC	10;10;10	G;T;C	10;10;10	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	240	porB1a	984	271	91.14	porB1a.l6.c30.ctg.2	436	18.3	0	.	p	.	0	F314I	NONSYN	940	942	TTC	267	269	ATC	12;12;12	A;T;C	12;12;12	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	240	porB1a	984	271	91.14	porB1a.l6.c30.ctg.2	436	18.3	0	.	p	.	0	A316S	NONSYN	946	948	GCG	273	275	TCG	12;11;11	T;C;G	12;11;11	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	240	porB1a	984	271	91.14	porB1a.l6.c30.ctg.2	436	18.3	0	.	p	.	0	V318A	NONSYN	952	954	GTC	279	281	GCC	10;10;10	G;C;C	8;10;10	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	240	porB1a	984	271	91.14	porB1a.l6.c30.ctg.2	436	18.3	0	.	p	.	0	G319S	NONSYN	955	957	GGC	282	284	AGC	11;11;12	A;G;C	10;11;12	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	240	porB1a	984	271	91.14	porB1a.l6.c30.ctg.2	436	18.3	0	.	p	.	0	G320A	NONSYN	958	960	GGT	285	287	GCC	12;12;12	G;C;C	12;12;12	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	240	porB1a	984	271	91.14	porB1a.l6.c30.ctg.2	436	18.3	0	.	p	.	0	G322V	NONSYN	964	966	GGT	291	293	GTT	11;11;11	G;T;T	11;11;11	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2042	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1542	131.0	0	.	p	.	0	N38E	NONSYN	112	114	AAT	462	464	GAA	181;182;182	G;A;A	171;171;174	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2042	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1542	131.0	0	.	p	.	0	N134D	NONSYN	400	402	AAT	750	752	GAT	163;162;165	G;A;T	159;157;161	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2042	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1542	131.0	0	.	p	.	0	P175S	NONSYN	523	525	CCA	873	875	TCA	168;169;167	T;C,T;A	161;160,1;161	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2042	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1542	131.0	0	.	p	.	0	F222L	NONSYN	664	666	TTT	1014	1016	CTT	166;167;167	C,T;T;T	160,1;161;161	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2042	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1542	131.0	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1332	1334	GCA	119;116;115	G;C,A;A	118;105,1;114	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2042	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1542	131.0	0	.	p	.	0	D333V	NONSYN	997	999	GAC	1347	1349	GTC	110;110;110	G;T;C	107;107;105	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2042	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1542	131.0	1	SNP	p	G120K	1	.	.	358	360	AAG	708	710	AAG	182;183;183	A;A;G	177;178;176	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2042	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1542	131.0	1	SNP	p	D121N	0	.	.	361	363	GAC	711	713	GAC	182;183;182	G;A;C	175;173;177	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2042	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1542	131.0	1	SNP	p	A121D	1	.	.	361	363	GAC	711	713	GAC	182;183;182	G;A;C	175;173;177	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	7154	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4808	147.0	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1992	1994	AAT	151;152;156	A;A;T	147;149;152	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	812	rpsJ	312	312	100.0	rpsJ.l15.c17.ctg.1	1038	77.0	1	SNP	p	V57M	1	.	.	169	171	ATG	560	562	ATG	153;156;156	A;T;G	148;151;150	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
